Trials / Terminated
TerminatedNCT00543608
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- Arpida AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the clinical cure rates of two dosing regimens of iclaprim with vancomycin (every 12 hours \[q12h\]) in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | iclaprim | |
| DRUG | vancomycin |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-04-01
- Completion
- 2009-05-01
- First posted
- 2007-10-15
- Last updated
- 2009-02-13
Source: ClinicalTrials.gov record NCT00543608. Inclusion in this directory is not an endorsement.